China Resources Double-Crane Pharmaceutical Co Ltd (600062) — Strategic Asset Allocation Index
China Resources Double-Crane Pharmaceutical Co Ltd (600062) has a Strategic Asset Allocation Index of 31.8% as of June 2023. Strategic assets (PP&E of CN¥3.57 Billion plus long-term investments of CN¥-) total CN¥3.57 Billion, measured against net assets of CN¥11.24 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See China Resources Double-Crane Pharmaceuti net asset quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
China Resources Double-Crane Pharmaceutical Co Ltd Strategic Asset Allocation Index (2000–2021)
This chart shows how China Resources Double-Crane Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 22 annual periods from 2000 to 2021. As of June 2023, the index stands at 31.8%, representing strategic assets of CN¥3.57 Billion against net assets of CN¥11.24 Billion CNY. For live market cap and overall valuation, see market value of China Resources Double-Crane Pharmaceuti.
Annual Strategic Asset Allocation Index for China Resources Double-Crane Pharmaceutical Co Ltd (2000–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for China Resources Double-Crane Pharmaceutical Co Ltd from 2000 to 2021, covering 22 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See China Resources Double-Crane Pharmaceuti net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 28.2% | CN¥2.96 Billion | CN¥2.96 Billion | CN¥- | CN¥10.48 Billion | ▼ -0.3 pp |
| 2020 | 28.5% | CN¥2.67 Billion | CN¥2.67 Billion | CN¥- | CN¥9.38 Billion | ▼ -2.1 pp |
| 2019 | 30.6% | CN¥2.66 Billion | CN¥2.62 Billion | CN¥34.27 Million | CN¥8.68 Billion | ▼ -3.0 pp |
| 2018 | 33.6% | CN¥2.66 Billion | CN¥2.63 Billion | CN¥22.81 Million | CN¥7.91 Billion | ▲ +2.3 pp |
| 2017 | 31.2% | CN¥2.45 Billion | CN¥2.45 Billion | CN¥2.11 Million | CN¥7.85 Billion | ▼ -2.5 pp |
| 2016 | 33.8% | CN¥2.38 Billion | CN¥2.36 Billion | CN¥16.48 Million | CN¥7.04 Billion | ▼ -4.5 pp |
| 2015 | 38.3% | CN¥2.47 Billion | CN¥2.44 Billion | CN¥21.69 Million | CN¥6.43 Billion | ▲ +2.2 pp |
| 2014 | 36.1% | CN¥2.05 Billion | CN¥2.05 Billion | CN¥- | CN¥5.68 Billion | ▼ -5.3 pp |
| 2013 | 41.5% | CN¥2.21 Billion | CN¥2.21 Billion | CN¥- | CN¥5.34 Billion | ▼ -5.4 pp |
| 2012 | 46.9% | CN¥2.21 Billion | CN¥2.21 Billion | CN¥- | CN¥4.71 Billion | ▲ +1.0 pp |
| 2011 | 45.9% | CN¥2.00 Billion | CN¥2.00 Billion | CN¥- | CN¥4.34 Billion | ▲ +2.9 pp |
| 2010 | 43.0% | CN¥1.69 Billion | CN¥1.69 Billion | CN¥- | CN¥3.93 Billion | ▼ -1.2 pp |
| 2009 | 44.2% | CN¥1.56 Billion | CN¥1.56 Billion | CN¥- | CN¥3.53 Billion | ▲ +2.1 pp |
| 2008 | 42.1% | CN¥1.33 Billion | CN¥1.33 Billion | CN¥- | CN¥3.15 Billion | ▼ -4.8 pp |
| 2007 | 46.8% | CN¥1.11 Billion | CN¥1.11 Billion | CN¥- | CN¥2.36 Billion | ▼ -18.3 pp |
| 2006 | 65.1% | CN¥1.30 Billion | CN¥1.30 Billion | CN¥- | CN¥2.00 Billion | ▼ -14.5 pp |
| 2005 | 79.6% | CN¥1.54 Billion | CN¥1.54 Billion | CN¥- | CN¥1.94 Billion | ▼ -10.3 pp |
| 2004 | 89.9% | CN¥1.55 Billion | CN¥1.55 Billion | CN¥- | CN¥1.73 Billion | ▲ +0.2 pp |
| 2003 | 89.6% | CN¥1.54 Billion | CN¥1.54 Billion | CN¥- | CN¥1.72 Billion | ▲ +19.8 pp |
| 2002 | 69.8% | CN¥1.12 Billion | CN¥1.12 Billion | CN¥- | CN¥1.60 Billion | ▲ +8.5 pp |
| 2001 | 61.3% | CN¥912.88 Million | CN¥912.88 Million | CN¥- | CN¥1.49 Billion | ▲ +8.4 pp |
| 2000 | 52.9% | CN¥452.36 Million | CN¥452.36 Million | CN¥- | CN¥855.27 Million | — |